imu-131
imugene
[]
in the final overall survival analysis of the phase 1/2 herizon trial, her-vaxx+ soc chemotherapy to elicit a survival benefit in patients her2-overexpressing metastatic or advanced gastric/gastroesophageal junction adenocarcinoma. #gicsm #gi23 
Oncology news and insights from leading researchers and cancer centers.